CNBC
Weight loss drug maker sinks 25% after new safety data spooks investors
While the experimental drug met its key targets, analysts are concerned over the commercial opportunity due to side effects.
Related stories
CNBC
WorldJun 19, 2026 · 1 min
Zealand Pharma stock suffered its two worst days on record. Here's what's next for the weight loss drugmaker
CNBC
MarketWatch
WorldJun 8, 2026 · 1 min
Zealand Pharma loses a fifth of its value as many users gave up taking weight-loss drug during trial
MarketWatch
MarketWatch
WorldJun 8, 2026 · 1 min
Eli Lilly stock jumps after late-stage trial of next-generation weight-loss drug
MarketWatch
Bloomberg
ScienceJun 17, 2026 · 1 min
UniQure Shares Soar After FDA Reversal on Its Huntington’s Therapy
Bloomberg